OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety of antisense oligonucleotide and siRNA-based therapeutics
Xuan Chi, Philip Gatti, Thomas Papoian
Drug Discovery Today (2017) Vol. 22, Iss. 5, pp. 823-833
Closed Access | Times Cited: 231
Xuan Chi, Philip Gatti, Thomas Papoian
Drug Discovery Today (2017) Vol. 22, Iss. 5, pp. 823-833
Closed Access | Times Cited: 231
Showing 1-25 of 231 citing articles:
The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu, Jing Li, Maorong Fu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1422
Xiaoyi Hu, Jing Li, Maorong Fu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1422
Advances in the delivery of RNA therapeutics: from concept to clinical reality
James C. Kaczmarek, Piotr S. Kowalski, Daniel G. Anderson
Genome Medicine (2017) Vol. 9, Iss. 1
Open Access | Times Cited: 578
James C. Kaczmarek, Piotr S. Kowalski, Daniel G. Anderson
Genome Medicine (2017) Vol. 9, Iss. 1
Open Access | Times Cited: 578
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Xiulong Shen, David R. Corey
Nucleic Acids Research (2017) Vol. 46, Iss. 4, pp. 1584-1600
Open Access | Times Cited: 570
Xiulong Shen, David R. Corey
Nucleic Acids Research (2017) Vol. 46, Iss. 4, pp. 1584-1600
Open Access | Times Cited: 570
Clinical cancer nanomedicine
Joy Wolfram, Mauro Ferrari
Nano Today (2019) Vol. 25, pp. 85-98
Open Access | Times Cited: 380
Joy Wolfram, Mauro Ferrari
Nano Today (2019) Vol. 25, pp. 85-98
Open Access | Times Cited: 380
Thrombocytopenia following Pfizer and Moderna SARS‐CoV ‐2 vaccination
Eun‐Ju Lee, Douglas B. Cines, Terry Gernsheimer, et al.
American Journal of Hematology (2021) Vol. 96, Iss. 5, pp. 534-537
Open Access | Times Cited: 371
Eun‐Ju Lee, Douglas B. Cines, Terry Gernsheimer, et al.
American Journal of Hematology (2021) Vol. 96, Iss. 5, pp. 534-537
Open Access | Times Cited: 371
The approved gene therapy drugs worldwide: from 1998 to 2019
Cuicui Ma, Zhen-Ling Wang, Ting Xu, et al.
Biotechnology Advances (2019) Vol. 40, pp. 107502-107502
Closed Access | Times Cited: 280
Cuicui Ma, Zhen-Ling Wang, Ting Xu, et al.
Biotechnology Advances (2019) Vol. 40, pp. 107502-107502
Closed Access | Times Cited: 280
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study
Jörg Täubel, Wilfried Hauke, Steffen Rump, et al.
European Heart Journal (2020) Vol. 42, Iss. 2, pp. 178-188
Open Access | Times Cited: 280
Jörg Täubel, Wilfried Hauke, Steffen Rump, et al.
European Heart Journal (2020) Vol. 42, Iss. 2, pp. 178-188
Open Access | Times Cited: 280
Therapies targeting DNA and RNA in Huntington's disease
Edward J. Wild, Sarah J. Tabrizi
The Lancet Neurology (2017) Vol. 16, Iss. 10, pp. 837-847
Open Access | Times Cited: 270
Edward J. Wild, Sarah J. Tabrizi
The Lancet Neurology (2017) Vol. 16, Iss. 10, pp. 837-847
Open Access | Times Cited: 270
Synthetic materials at the forefront of gene delivery
Irene Lostalé‐Seijo, Javier Montenegro
Nature Reviews Chemistry (2018) Vol. 2, Iss. 10, pp. 258-277
Closed Access | Times Cited: 265
Irene Lostalé‐Seijo, Javier Montenegro
Nature Reviews Chemistry (2018) Vol. 2, Iss. 10, pp. 258-277
Closed Access | Times Cited: 265
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
Suzan M. Hammond, Annemieke Aartsma‐Rus, Sandra Alves, et al.
EMBO Molecular Medicine (2021) Vol. 13, Iss. 4
Open Access | Times Cited: 253
Suzan M. Hammond, Annemieke Aartsma‐Rus, Sandra Alves, et al.
EMBO Molecular Medicine (2021) Vol. 13, Iss. 4
Open Access | Times Cited: 253
Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis
Wei Chen, Aiting Yang, Jidong Jia, et al.
Hepatology (2020) Vol. 72, Iss. 2, pp. 729-741
Closed Access | Times Cited: 189
Wei Chen, Aiting Yang, Jidong Jia, et al.
Hepatology (2020) Vol. 72, Iss. 2, pp. 729-741
Closed Access | Times Cited: 189
Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naïve to Nucleos(t)ide Therapy
Michel Bazinet, Victor Pântea, Gheorghe Plăcintă, et al.
Gastroenterology (2020) Vol. 158, Iss. 8, pp. 2180-2194
Open Access | Times Cited: 188
Michel Bazinet, Victor Pântea, Gheorghe Plăcintă, et al.
Gastroenterology (2020) Vol. 158, Iss. 8, pp. 2180-2194
Open Access | Times Cited: 188
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
Michael J. Koren, Patrick M. Moriarty, Seth J. Baum, et al.
Nature Medicine (2022) Vol. 28, Iss. 1, pp. 96-103
Closed Access | Times Cited: 181
Michael J. Koren, Patrick M. Moriarty, Seth J. Baum, et al.
Nature Medicine (2022) Vol. 28, Iss. 1, pp. 96-103
Closed Access | Times Cited: 181
Cancer the‘RBP’eutics–RNA-binding proteins as therapeutic targets for cancer
Shakur Mohibi, Xinbin Chen, Jin Zhang
Pharmacology & Therapeutics (2019) Vol. 203, pp. 107390-107390
Open Access | Times Cited: 156
Shakur Mohibi, Xinbin Chen, Jin Zhang
Pharmacology & Therapeutics (2019) Vol. 203, pp. 107390-107390
Open Access | Times Cited: 156
Precision Cancer Nanotherapy: Evolving Role of Multifunctional Nanoparticles for Cancer Active Targeting
Anas Ahmad, Farheen Khan, Rakesh Kumar Mishra, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 23, pp. 10475-10496
Closed Access | Times Cited: 152
Anas Ahmad, Farheen Khan, Rakesh Kumar Mishra, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 23, pp. 10475-10496
Closed Access | Times Cited: 152
Nanotechnology for cardiovascular diseases
Qinqin Hu, Zheyan Fang, Junbo Ge, et al.
The Innovation (2022) Vol. 3, Iss. 2, pp. 100214-100214
Open Access | Times Cited: 71
Qinqin Hu, Zheyan Fang, Junbo Ge, et al.
The Innovation (2022) Vol. 3, Iss. 2, pp. 100214-100214
Open Access | Times Cited: 71
Alternatives Therapeutic Approaches to Conventional Antibiotics: Advantages, Limitations and Potential Application in Medicine
Hiba Alaoui Mdarhri, Rachid Benmessaoud, Houda Yacoubi, et al.
Antibiotics (2022) Vol. 11, Iss. 12, pp. 1826-1826
Open Access | Times Cited: 70
Hiba Alaoui Mdarhri, Rachid Benmessaoud, Houda Yacoubi, et al.
Antibiotics (2022) Vol. 11, Iss. 12, pp. 1826-1826
Open Access | Times Cited: 70
Targeting and engineering long non-coding RNAs for cancer therapy
Michela Coan, Simon Haefliger, Samir Ounzain, et al.
Nature Reviews Genetics (2024) Vol. 25, Iss. 8, pp. 578-595
Closed Access | Times Cited: 60
Michela Coan, Simon Haefliger, Samir Ounzain, et al.
Nature Reviews Genetics (2024) Vol. 25, Iss. 8, pp. 578-595
Closed Access | Times Cited: 60
Antisense oligonucleotides: a novel Frontier in pharmacological strategy
Debora Collotta, Ilaria Bertocchi, E. Chiapello, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 56
Debora Collotta, Ilaria Bertocchi, E. Chiapello, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 56
Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation
Jillian Belgrad, Hassan H. Fakih, Anastasia Khvorova
Nucleic Acid Therapeutics (2024) Vol. 34, Iss. 2, pp. 52-72
Closed Access | Times Cited: 32
Jillian Belgrad, Hassan H. Fakih, Anastasia Khvorova
Nucleic Acid Therapeutics (2024) Vol. 34, Iss. 2, pp. 52-72
Closed Access | Times Cited: 32
Frameworks for transformational breakthroughs in RNA-based medicines
John R. Androsavich
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 6, pp. 421-444
Closed Access | Times Cited: 22
John R. Androsavich
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 6, pp. 421-444
Closed Access | Times Cited: 22
How We Think about Targeting RNA with Small Molecules
Matthew G. Costales, Jessica L. Childs‐Disney, Hafeez S. Haniff, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 17, pp. 8880-8900
Open Access | Times Cited: 134
Matthew G. Costales, Jessica L. Childs‐Disney, Hafeez S. Haniff, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 17, pp. 8880-8900
Open Access | Times Cited: 134
RNA-Binding Proteins in Cancer: Functional and Therapeutic Perspectives
Donghee Kang, Yerim Lee, Jae‐Seon Lee
Cancers (2020) Vol. 12, Iss. 9, pp. 2699-2699
Open Access | Times Cited: 128
Donghee Kang, Yerim Lee, Jae‐Seon Lee
Cancers (2020) Vol. 12, Iss. 9, pp. 2699-2699
Open Access | Times Cited: 128
Targeting RNA : A Transformative Therapeutic Strategy
Wei Yin, Mark Rogge
Clinical and Translational Science (2019) Vol. 12, Iss. 2, pp. 98-112
Open Access | Times Cited: 125
Wei Yin, Mark Rogge
Clinical and Translational Science (2019) Vol. 12, Iss. 2, pp. 98-112
Open Access | Times Cited: 125
Delivery of MicroRNAs by Chitosan Nanoparticles to Functionally Alter Macrophage Cholesterol Efflux in Vitro and in Vivo
My-Anh Nguyen, Hailey Wyatt, Leah C. Susser, et al.
ACS Nano (2019) Vol. 13, Iss. 6, pp. 6491-6505
Closed Access | Times Cited: 119
My-Anh Nguyen, Hailey Wyatt, Leah C. Susser, et al.
ACS Nano (2019) Vol. 13, Iss. 6, pp. 6491-6505
Closed Access | Times Cited: 119
